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Strategy for the Assessment of
Neurobehavioral Consequences of
Environmental Factors
by Hugh A. Tilson* and Patrick A. Cabe*
One ofthe critical issues confronting theevolving disciplineofbehavioral and neurological toxicology is
the general lack of test validation in animal models. This paper seeks to provide a strategy aimed at
resolving this important problem. It is proposed that test validation beaccomplished byevaluating known
neurotoxins in a battery oftests chosen to assess in animal models a wide range ofeffects on the basis of
reported human toxicosis symptomatology. We propose to measure ongoing home cage motor activity,
food consumption, water consumption, clay consumption (and the diurnal cycling of these),
neurological/physiological indices (reflexes, autonomic signs, equilibrium/gait, balance, tremor, reactiv-
ity, and muscular strength), and aspects ofcognitive and associative behavior involving both endogenous
and exogenous (sensory) control ofresponding. An integrated, time-efficient scheme, covering 90 days of
chemical treatment and 30 days of post-dosing recovery will be used.
Chemical substances to be evaluated were chosen with the view of representing classes of neurotoxic
effects. For initial study, triethyltin was chosen as an agent producing demyelination of nerves, ac-
rylamide as an agent producing "dying-back" neuropathy, and methylmercury as an agent producing
mixed central and peripheral neuropathies. Agents which attack specific loci in the nervous system and
those producing anoxia will not be assessed in the first stages of this research due to lack of species
generality of known effects, present lack of appropriate exposure facilities, or other problems. In addi-
tion, two drugs (amphetamine and sodium salicylate) will be investigated to support the generality ofthe
testing procedures.
By comparing the observed results of the neurotoxins in the animal models with the predicted effects
based on reported human symptomatology, some decision concerning the validity ofeach procedure wiln
be made. It isexpected that the validation ofteststo be used in behavioral and neurological toxicology will
permit the meaningful assessment ofmore complex issues, such as the mechanisms by which neurotoxins
act.
Introduction
General Aspects of Environmental
Toxicology
The patent and potential hazards of exposure to
environmental factors such as irradiation, noise,
and chemical agents have become of increasing
concern to many segments of society. Ofparticular
importance are the possible consequences of con-
tact with the vast number of pharmaceutical, in-
dustrial, and agricultural chemicals and their by-
products that have entered the environment in re-
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cent years. The benefits yielded by modern
technology are clear and, in many parts of the
world, the use of products such as pesticides and
herbicides contributes directly to human survival.
However, even highly useful chemical agents may
persist in the environment and incidental exposure
of nontarget organisms, including man, to such
agents is inevitable. Unfortunately, some of these
chemical contaminants affect nontarget biological
systems adversely, either directly or through in-
teraction with other environmental factors.
It is clear, therefore, that evaluation of the risk
following from exposure to pollutants is required.
Environmentaltoxicology is the emergentdiscipline
devoted to the study of toxic effects of environ-
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to human exposure and health. Recognition of the
problems entailed in environmental toxicology has
evoked at least two major responses from the Fed-
eral government. First, regulatory agencies, such as
the Environmental Protection Agency (EPA), Food
and Drug Administration (FDA), and Occupational
Safety and Health Administration (OSHA) have
been assigned the responsibility and authority to
regulate the levels ofchemicals already in, or which
might enter, the environment. These governmental
agencies also attempt to predict potential ill effects
ofnewly developed chemical entities and to control
human exposure to compounds which may be
hazardous. For example, in response to the possi-
bility that contact with chemical products may be
involved in the etiology of cancer, the Congress of
the United States enacted the Toxic Substances
Control Act of 1976. This legislation provides the
legal basis for the screening or mass testing for pos-
sible carcinogenicity and other effects ofnewly de-
veloped chemicals prior to their being marketed.
A second major consequence of the acknowl-
edgment of the hazard of toxic substances in the
environment has been an increased awareness that
the solution of environmental toxicological prob-
lems will require multidisciplinary and interdiscipli-
nary efforts, with contributions necessarily coming
from many segments of the biomedical research
community. Scientists from many fields ofexpertise
are now studying the biological effects of toxic
agents. Intensive efforts are currently under way at
centers such as the National Institute of Environ-
mental Health Sciences (NIEHS), the National
Center forToxicological Research (NCTR), and the
National Institute of Occupational Safety and
Health (NIOSH) to identify the causes, conditions,
effects, and mechanisms of toxicosis.
Evolution of Behavioral Toxicology
In neurotoxicology, the study of toxicities af-
fecting the nervous system, investigators employing
methodologies derived from experimental psychol-
ogy, neurology, neurophysiology, and psycho- and
neuropharmacology have begun to form the basis of
a new discipline (1, 2). The scope and findings of
this newly evolved area of research, generally
termed behavioral toxicology, have been the sub-
ject of several recent reviews and books (3-7).
A critical assertion in behavioral toxicology is
that the behavior of organisms represents the net
result of various sensory, motor and associative
functions of the nervous system. Thus, alterations
in behavior that follow exposure to low concentra-
tions oftoxins may be the result ofsubtle changes in
nervous system function. An important corollary of
this argument is that behavioral changes may pre-
cede histopathological or morphological changes in
nerve tissue and thereby prove to be a highly sensi-
tive component in toxicological evaluations. In fact,
many countries, most notably the Soviet Union,
have relied heavily upon behavioral tests in their
toxicology testing for several years, and it is rele-
vant to this point that the acceptable limits ofmany
toxic substances in the Soviet Union are below
those established in this country (8, 9). This kind of
precedent has stimulated the use ofbehavioral toxi-
cological testing in the United States, with the sub-
sequent reduction ofacceptable limits for chemicals
such as trichloroethylene (5).
Although behavioral techniques have become
relatively commonplace in drug evaluations, recog-
nition oftheir utility in environmental toxicology is
a comparatively recent development (1). In fact,
some investigators have pointed out the limited
agreement as to the sensitivity and utility of many
commonly used behavioral tests and procedures
(10). The Subtask Force on Disease and Injury,
Special Problems, ofthe Second Task Force for Re-
search Planning in Environmental Health Sciences
(11) lends support to this assertion by recommend-
ingthe development ofstrategies forthe selection of
behavioral procedures for safety evaluation. It is
our position that little meaningful progress can be
made in behavioral and neurological toxicology
until such a strategy has been developed.
In an embryonic area of inquiry, such as be-
havioral and neurological toxicology, early consen-
sus on aims, strategies, and accepted procedures is
unlikely. However, the critical environmental is-
sues that have been and continue to be raised
strongly suggest that some effort be made toward
providing a relatively coherent, systematic
framework for research in this area. It is anticipated
that such an attempt would at least provide a basis
for discussion among researchers in this field. It is
hoped that this interaction will lead to agreement
concerning basic research strategy, since this ac-
cord should make finding solutions to the critical
issues more efficient. A set of common reference
points should also facilitate integration of research
findings and help establish the credibility ofthe dis-
cipline in the eyes of other scientists, adminis-
trators, legislators, and laymen who must cope with
the problems of environmental safety.
In this paper, the issue oftest validity as the out-
standing problem for current research in behavioral
and neurological toxicology is discussed. Included
here are critical issues related to test validation,
among which are criteria for selection ofbehavioral
tests, representative neurotoxins, animal models,
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specific research program, the goal of which is to
provide a valid screening procedure to assess
neurobehavioral effects of potentially hazardous
environmental factors. The last section presents a
matrix ofpredicted effects ofrepresentative chemi-
cals on selected behavioral and physiological mea-
sures.
Overview of Critical Issues
Concerning Research in
Behavioral and Neurological
Toxicology
Goals and Aims
Neurotoxicologists are confronted with such
questions as the mechanisms by which toxins affect
the nervous system, the identification of variables
that affect the manifestations of toxicosis, and the
detection and prediction of neurotoxicity following
exposure to low amounts of environmental agents.
However, before these interesting and intriguing
topics can be systematically investigated, we be-
lieve that there is another issue that must be re-
solved first, and this is the problem of test valida-
tion (12). We feel that is is imperative first to con-
sider whether or not the tests and methods used in
behavioral and neurological toxicology actually
measure what they are intended to measure, and
whether or not the dataobtained from some types of
animal models can be logically extrapolated to the
human case. To proceed further without first
addressing the problem of test validation is, in our
opinion, premature and unwarranted.
We believe that the most logical approach to the
validation ofsensitive and reliable methodologies is
to compare compounds known to have specific
neurotoxic effects in a battery of tests chosen to
detect a wide range of possible effects and to over-
lap in terms of signs evaluated. By using such a
battery, it should be possible to generate aprofile of
effects characteristic of each compound. This pro-
file could then be used to evaluate the sensitivity
and selection ofthose tests assumed to measure the
same neurobehavioral functions. This strategy per-
mits test validation by showing the similarities be-
tween procedures assumed or purported to measure
the same function and by providing a distinction
between procedures assumed to measure different
processes. This approach to test validation has been
described as the multitrait-multimethod process of
validation (13).
Choice of Tests for Assessment of
Neurotoxicity
We believe that tests used to assess toxicity in the
nervous system should reflect the full range ofsigns
and symptoms reported by humans exposed to
neurotoxins. Table 1 summarizes the behavioral
and neurological sequelae ofhuman neurotoxicosis;
as can be seen, the set ofsymptoms may be grouped
into subcategories of neurobehavioral functions.
These include areas of sensory function, motor
strength and coordination, associative or cognitive
factors, emotionality, and several other symptoms
less easily described by a short label (e.g., insom-
nia, anorexia, hyper- or hypothermia). Thus, selec-
tion of neurobehavioral tests should reflect, in a
reasonably representative fashion, these areas of
neurobehavioral function.
In addition to the relationship between functional
tests and potential human symptomatology, there
are practical constraints imposed by characteristics
of the animal model of choice, the availability of
technology for taking the measure, and the cost-
effectiveness/time-efficiency factors entailed by the
numbers of subjects and numbers of compounds to
be tested. Further complications are raised by the
generally acknowledged trade-offbetween sensitiv-
ity and complexity of tests and by the frequent de-
sirability ofimposing multiple testing procedures on
the same subjects. The timing and sequencing of
Table 1. Symptomatology reported by humans
exposed to neurotoxins.
Function affected Symptomatology
Sensory Anosmia
Paresthesias in feet, fingers, toes
Visual deficits, photophobia, nystagmus
Auditory deficits, tinnitus
Perceptual dysfunctions, pseudohallucina-
tions
Motor Weakness in hands, arms, legs, paralysis
Incoordination, dizziness
Fatigue
Tremor, convulsions
Hyperactivity
Slurred speech
Affective Nervousness, irritability, agitation,
euphoria, psychosis
Apathy, lethargy, depression, compulsive
behavior
Associative Impaired short term memory
(cognitive) Impaired long term memory
Confusion, disorientation
Physiological and Disrupted sleep-awake cycles
consummatory Hypothermia, hyperthermia, sweating
responses Loss of stimulated appetite
Loss or gain in body weight
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mechanism of action.
General mechanism
of neurotoxicity Compounds
Agents that produce Triethyltin
demyelination Hexachlorophene
Agents that produce "dying Acrylamide
back" neuropathies DDT
Leptophos
Kepone
Agents that produce mixed Methylmercury
central and peripheral Inorganic lead
neuropathies Carbon disulfide
Tellurium
Agents affecting specific Manganese
CNS nuclear groups Monosodium glutamate
Salicylates
Agents that produce Carbon monoxide
neurotoxicity through Cyanides and cyanates
hypoxia or anoxia Azide
Agents whose mechanism of Polybrominated biphenyls
neurotoxicity in humans is 2,3,5-Trichlorophenoxy-
not yet well defined acetic acid
Tetraethyllead
treatments and procedures within the relatively
limited lifetime ofa typical individual ofthe species
under test are perhaps the final practical boundary
conditions on choosing test procedures. Preferred
tests are those which are reliable, robust, sensitive,
time-efficient, and cost-effective.
Choice ofRepresentative Agents to Be Used
in Validation of Behavioral Tests
It is our position that neurotoxins used for vali-
dation ofbehavioral methods should be selected on
thebasis ofknown symptomatology andmechanism
or site of action from a standard classification of
neurotoxins incorporating those factors described
by Norton (14). Table 2 summarizes Norton's clas-
sification with minor modifications and lists rep-
resentative compounds in each category.
A second criterion to be used in the selection of
candidate neurotoxins for validity testing is that
each should be capable ofproducing neurotoxic ef-
fects in the animal model. For example, tri-o-cresyl
phosphate produces "dying-back" neuropathies in
many species, but it is less active in rodent species.
Thus, ifthe rat were chosen as the animalfor study,
the neurotoxicity of this agent might be detected
only after very high doses.
Forpurposes ofcomparison between humans and
an animal model, it is desirable that adequate infor-
mation concerning the absorption, distribution,
metabolism, and dwelltime inthe body (half-life) be
available.
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Animal Models
The extrapolation of animal toxicological data to
man is always tenuous, but, for obvious reasons,
animal test models are necessarily used. Unfortu-
nately, there is no single animal model in which
effects correlate perfectly with toxicity in humans.
In the selection of a suitable animal test model, the
following points need to be considered.
Ifthe purpose of a research program is to provide
a basis for the development of a test battery to be
used in the mass screening of known or suspected
environmental toxins, there are obvious economic
factors that must be taken into account. In addition
to the need for a reasonable cost per experimental
subject, factors such as housing and maintenance
costs must also be considered, since repeated dos-
ing procedures require adequate space to house
large numbers of subjects plus provision for hus-
bandry of them over extended periods of time.
It is also imperative that there be an adequate
pharmacological and toxicological data base on the
species chosen for study, such that meaningful in-
terpretations of chemically induced effects can be
made and appropriate hypotheses about mechanisms
and loci of action can be framed.
The use of a single animal species in most, if not
all, of the behavioral tests will facilitate compari-
sons among measures and will help determine the
reliability and sensitivity of behavioral methods.
Weight should, therefore, be given to those species
or strains to which multiple procedures are known
to be applicable.
The researcher must also consider various or-
ganismal variables. For example, the estrous cycle
of female rats may introduce an additional un-
wanted variance component into the data of some
behavioral tests (15). Somejustification or explana-
tion for the use of female subjects in behavioral
toxicological studies would, therefore, be war-
ranted. Another organismal variable is the age of
the subject. Developing organisms and older, se-
nescent animals differ from the mature adult in
their sensitivities to chemicals (8). Unless the re-
search program is specifically aimed at elucidating
the effects ofchemicals in the developing animal or
in older animals, mature adult organisms should be
considered as the normative population. We believe
that the initial use ofthe mature, adult organism will
provide the opportunity for establishing something
of a benchmark against which the possible interac-
tions of age and chemically induced toxicosis can
better be evaluated.
Dosing and Route of Administration
Studies in behavioral and neurological toxicology
Environmental Health Perspectivesinvolve either single or repeated exposures to the
agent being investigated. Assuming that detection
of cumulative toxicity following exposure to sub-
threshold doses is a major research goal, a sub-
acute, multiple-dosing regimen that spans about
one-tenth of the expected life span of the tested
subject is a typical paradigm (16). For example, if
the rat were chosen as the animal model, the appro-
priate dosing period would be three to four months.
Neurobehavioral assessments should also be ad-
ministered for a time following cessation of the
dosing regimen since it would be of interest to de-
termine the reversibility ofany effects noted during
the dosing phase, or possibly to note any delayed
post-dosing effects.
In many neurotoxicological studies using a sub-
acute dosing regimen, the rationale for the doses
chosen is often missing. One procedure frequently
employed to arrive at doses for subacute studies is
to use multiples of a previously determined LD50
(i.e., dose required to cause lethality in 50%o of the
animals dosed). One alternative to this approach, at
least in the study ofanticancer drugs, is to use mul-
tiples of the lethal dose (LD), which is defined as
the lowest dose producing death in any subject
during the period of examination (17). However,
because the dose response curves ofvarious toxins
differ greatly in slope, it is unlikely that either of
these two approaches can be used as a standard
strategy. Instead, some portion (i.e., one-tenth) of
the LD50 or LD might be used in a short-term (e.g.,
30 days) dose-ranging study designed to detect a
cumulative toxic dose (CTD). Once such adose has
been identified, the portions of the CTD might be
used in a longer, subacute dosing study.
The acceptance of behavioral and neurological
toxicology as a discipline will largely depend upon
adherence to basic principles of pharmacological
and toxicological research. We believe that it is im-
perative to establish dose-response relationships
between chemicals and behavior, and to study time
to the onset, and duration of the observed effects
and the cumulative dose required to elicit toxicosis.
Under optimal conditions, researchers would be
aware ofthe levels ofthe agent in the plasma ofthe
subject at the time of testing and would know
something about the absorption, distribution and
metabolism ofthe chemical being evaluated.
The choice ofroute ofadministration is a critical
one for the behavior toxicologist. The chemical's
route ofentry into the body should be similar to that
encountered in the environment. However,
adequate facilities for some routes, e.g., inhalation,
may not be available and alternative routes should
be considered. Since the oral route is frequently
encountered, it could be used in most routine toxi-
cological assessments. Ofthe two usual methods of
oral administration, intubation is preferred over in-
gestion through the diet or drinking water since the
amount ofchemical delivered to the subject is more
precisely controlled.
Finally, the extrapolation of toxicological data
from small animals such as the rat to humans is
reportedly more precise ifdose levels are calculated
on the basis ofbody surface area, rather than body
weight (18). Researchers using small rodents might
consider using the two-thirds power of the body
weight factor described to estimate body surface
area (19).
Proposed Research Program in
Behavioral And Neurological
Toxicology
General Overview of Proposed Research
The purpose ofthe following research program is
to validate behavioral toxicological methods in ani-
mals that may be predictive of human behavioral
change in toxicosis. As discussed in the previous
section, validation ofbehavioral procedures will be
attempted using representative neurotoxins in a
battery oftests designed to measure many possible
signs of toxicosis.
Testing Strategy. As part ofour efforts to vali-
date behavioral methodology, two levels of testing
willbe employed. Atthefirstlevelofevaluation, we
will use two batteries of tests, the domiciliary and
primary screen. In the domiciliary battery we will
investigate toxin-related changes in food and water
consumption, ingestion ofa nonnutritive substance
and general motor activity. These measures are
known to be diurnally cyclic and periodicities of
each will therefore be observed.
A separate group of subjects will be examined
periodically in the primary screening tests during
exposure to toxins. This battery oftests will consist
of body weight measurements and observational
ratings of reflexive and physiological functioning.
Tests requiring little or no training and having the
capacity to test the same subjects repeatedly will be
used to assess toxin-related changes in sen-
sorimotor function and CNA excitability. The ac-
quisition and retention of a simple discriminated
avoidance task will also be evaluated.
Ifsigns ofbehavioral or neurological toxicity are
observed in the domiciliary or primary screen tests,
additional evaluation will occur using procedures
thought to be sensitive to subtle changes in sensory,
memory, associative capabilities, and/or psy-
chomotor functioning (special tests). Many ofthese
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evaluation and/or manipulation of motivational
factors, such as food deprivation or electric foot-
shock. For this reason, the lowest dose producing a
significant effect in the domiciliary or primary
screen tests will be used at first in validation of the
special tests. Ifit appears that a special test permits
the detection ofan effect at a lower cumulative dose
than that observed in the domiciliary or primary
screen tests, lower doses of the chemical will be
evaluated.
Depending upon the effect observed in the
domiciliary and primary screen tests, one or more
of the following special tests or tests to be de-
veloped will be considered: measures of pain or
reaction threshold, acquisition and retention of an
active avoidance response, performance of a tem-
porally based discrimination with and without im-
posed stimulus-response delays, conditioned sup-
pression of baseline responding by auditory and
visual stimuli paired with electric footshock, and
responding on an unsignalled continuous avoidance
schedule.
Subjects and GroupAssignments. We propose
to use adult male albino rats of the Fisher strain in
all studies. Those subjects in the domiciliary test
will be housed individually in special cages designed
to measure ingestive and motor behaviors. Those
animals used for the primary screen and special
tests will be housed singly or in groups of two to
four, depending upon the procedure employed.
In the domiciliary and primary screen tests, ani-
mals will be assigned randomly to one of five ex-
perimental groups: nondosed control, vehicle-
treated control, and three dosed groups. Unless
needed otherwise, only a vehicle treated control
group and a treatment group will be used in the
special tests. Enough subjects will be used to insure
reliable and stable statistical evaluation of results.
Scheduling of Dosing and Testing. Prior to
the start ofthe subacute dosing study, a cumulative
toxic dose (CTD) will be ascertained by dosing ani-
mals for 30 days with 1/10 or 1/100ofthe reported or
empirically derived oral LD50. Dosing will be by
gavage, Monday through Friday. Selected be-
havioral tests from the primary test battery will be
used to determine any cumulative toxicity. Once a
CTD has been determined in the 30 day dose-
ranging study, portions ofthe CTD (1, 1/2, or 1/4) will
be used in the 90-day subacute study. Dosing will be
by gavage on Mondays, Wednesdays, and Fridays
after all behavioral tests have been completed. Be-
havioral and neurological assessments will occur in
the week prior to dosing (predosing phase) and in
the first week and every third week thereafter dur-
ing the 90 day dosing phase. Tests will also be given
during the second and fourth weeks of a 30 day
post-dosing phase. Special tests will be adminis-
tered on a session-by-session basis. The schedule of
behavioral testing is summarized in Table 3.
Blood samples will be drawn as neededjust prior
to dosing on-the Friday of each week in which pri-
mary screen tests occur. At the end of the entire
series, some animals will be euthanized and the
brain will be.analyzed for histopathology. Other tis-
sue analyses may also be run on a discretionary
basis at that time.
Table 3. Schedule of behavioral testing.
Test battery Time of testing Variables
Domiciliary Daily for 120 days Frequency and patterning of
motor activity, drinking,
eating, and kaolin ingestion
Primary screen During predosing phase, Gross behavioral ratings
every third week of Body weight
dosing phase and during Spontaneous motor activity
second and fourth week of Visual placement
post-dosing phase Forelimb grasping
Hindlimb extensor response
Performance on inclined screen
Startle and habituation
Tremor
Rectal temperature
At 45 days Acquisition ofactive avoidance
At 90 days Retention of avoidance
Special tests Session-by-session Temporal discrimination
Unsignalled continuous avoidance
Conditioned suppression
Shock titration-pain thresholds
At 45, 90, or 120 days Shuttle box or passive avoidance
learning
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Tests
Domiciliary Tests. A general principle in
psychology and animal behavior is that the behavior
of an organism is likely to be stable and predictable
given stable environmental conditions. Another
way of saying this is that the probability of occur-
rence of a given response is relatively fixed under
unchanging environmental conditions. It follows
more or less directly that differences in response
probabilities as a function of chemical administra-
tion could be used as indicators of toxicity. In a
sense, this theme is characteristic of all behavioral
toxicological testing, the major difference being in
the initial probability of the response in question
(i.e., its baseline rate).
Some responses in any organism's behavioral re-
pertoire are highly probable, some others less so.
The measures we propose to take will sample from
several levels of response probability. In some, the
special tests, response probabilities are actively
manipulated through control of stimulus, motiva-
tional, and response contingency conditions. In the
primary screen tests, the observation of at least
some responses is made more probable by imposing
appropriate stimulus conditions, e.g., a toe pinch or
a touch on the cornea. In the domiciliary test, mea-
sures of high probability responses tend to be con-
trolled by internal conditions or states of the or-
ganism over relatively extended observation
periods (24 hr) (20). Such measures include eating,
drinking, general locomotor activity, and kaolin
clay consumption (geophagia) and are related to the
ecological and evolutionary history ofthe organism.
On the principle that treatment with toxic sub-
stances should be discernible in changes in proba-
bility ofoccurrence ofa response, it is reasonable to
assume that changes in feeding, drinking, and ac-
tivity patterns will be reliable indicators of tox-
icosis. Since general cage activity in the domiciliary
cage is but a fraction ofthe animals' total repertoire
of spontaneous activity, other tests and apparatus
that examine wheel running, exploratory, rearing,
and grooming behavior may be necessary. Indi-
vidual and multivariate assessments of these be-
haviors will be made to establish baselines for de-
tecting and quantifying the onset and presence of
low level toxicosis.
Geophagia, as a further measure, is a low-
probability response in normal rats under normal
conditions. An increase in the probability ofthe oc-
currence ofgeophagia, however, has been observed
under conditions known to produce illness in other
species (21).
While it is clear that toxicologists and psy-
chopharmacologists have looked at measures of in-
gestion and locomotor activity as indicators of
chemical effects, the scheme proposed here departs
significantly from past practice in two respects: (a)
its emphasis on cyclicity in those measures and (b)
in the introduction of a measure of ingestion of a
nonnutritive substance known to be related to ill-
ness.
Primary Screening Tests. It is relatively stan-
dard practice in the evaluation of chemical agents
suspected of having effects on the nervous system
to subjectanimals dosed with the agent to a series of
simple tests and observational procedures. An
example of this approach is detailed by Irwin (22).
While some of these are not what might be consid-
ered behavioral in some pure sense, the measures,
taken together, are indicative of the functional in-
tegrity of the nervous system.
The measures to be examined fall roughly into
categories of neurological screening and general
health, activity/reactivity, and sensorimotor func-
tioning.
NEUROLOGICAL SCREENING AND GENERAL
HEALTH. Autonomic signs will be scored as pres-
ent orabsent and include observations ofsalivation,
lacrimation, piloerection, exophthalmus, abnormal
skin color (further scored as blanched, flushed, or
cyanotic if abnormal), and diarrhea. Rectal temper-
ature and body weight measurements will also be
taken. Subjects dying during the study will be ne-
cropsied for signs of organ disease and pathology
possibly related to chemical exposure.
Reflex responses will be scored as normal or de-
pressed for the following: left and right pinna re-
flexes, left and right eye-blink, left and right ipsilat-
eral flexor reflex, righting reflex, and reflexive re-
sponsiveness to pain (tail pinch). The response to
tail pinch will be rated as to its intensity as well.
ACTIVITY/REACTIVITY. In addition to the mea-
sure ofactivity obtained in the domiciliary test bat-
tery, motor activity will be measured at regular
intervals in commercially available activity cham-
bers. Changes in CNS excitability will be measured
in the form ofstartle response magnitude and rapid-
ity of acclimation to a repeated external stimulus
such as an air puff, acoustic, or visual signal (23).
Included in the category ofreactivity is the ability
of the subjects to acquire a one-way shock-
motivated avoidance response to a combined
light-tone signal as described by Clark (24). Acqui-
sition will be measured after 45 days of dosing and
retention will be assessed after 90 days ofdosing. If
effects are evident at 90days, retesting will occur30
days after cessation of dosing.
SENSORIMOTOR FUNCTIONING. Possible motor
dysfunction will be assessed using several indepen-
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be tested by using a recording grip meter (25, 26),
while hindlimb extensor reflexes will be evaluated
by a technique recently developed in our Labora-
tory. Overall grip strength and coordination will be
assessed by performance on the inclined screen
(26). Fine motor fasciculations (tremor) will be
evaluated by means of a transduction-amplication-
recording system similar to that described by Hen-
derson and Wooley (27). Orientation to sensory
stimulation will be tested using a battery such as
that described by Marshall and Teitelbaum (28).
Head orientation or biting will be scored to presen-
tations of odors, tactile stimulation, visual motion,
and auditory clicks. Body orientation to tilt, lateral
hopping, and fore and hind paw placing will also be
tested.
Special Tests. Ofthe many symptoms reported
in clinical cases of toxicosis, perhaps the most dif-
ficult ones for which animal models are needed are
effects having to do with what might broadly be
termed cognitive processes, those involving the ac-
quisition and processing of information, the utiliza-
tion of response-consequence contingencies,
decision-making, and response-initiating functions.
By selectively using the paradigms described
below, we will attempt to relate toxicosis to changes
in behaviors suspected of being correlated with
higher-level nervous system functions listed above.
PAIN THRESHOLDS. Footshock titration proce-
dures have been used to detect both increases and
decreases in nociceptive thresholds (29, 30). Re-
cently, Sideroff and Santolucito (31) reported that
the insecticide carbaryl decreased the sensitivity of
rats to electric shock, for example.
Because of the apparent utility of operant proce-
dures in the determination of aversion thresholds,
rats will be tested in a paradigm similar to that of
Weiss and Laties (32, 33). After training in 40 min
daily sessions, rats will be tested twice weekly dur-
ing 90 days of dosing and the 30 day post-dosing
period. Median shock intensity during each half of
the session will be determined.
SHUTTLE Box AVOIDANCE AcQuISITION. The
capability of rats to acquire an avoidance response
in the shuttle box is a standard psychophar-
macological test oflearning and memory in the rat.
The subjects will be dosed for 45 days and then
given 120 massed acquisition trials in the shuttle
box (34). The same subjects will be retested in an
identical fashion at 90 days of dosing. If significant
effects are observed during the 45- and 90-day tests,
subsequent tests will be given at the end of the 30
days of post-dosing recovery.
UNSIGNALLED CONTINUOUS AVOIDANCE. This
procedure has been used extensively in the evalua-
tion of psychoactive drugs. Since behavior is not
under the control of external stimuli, it should be
sensitive to changes in central nervous system
(CNS) function (35). Rats will be trained to post-
pone electric footshock on an unsignalled continu-
ous schedule (34). Training sessions will occurdaily
until a stable baseline ofresponding has been estab-
lished. The rats will then be matched according to
baseline rates, assigned to groups, and run twice
weekly for the duration of the experiment.
Avoidance and escape responses, escape losses,
and distribution of lever-press interresponse times
(IRT) will be recorded.
CONDITIONED SUPPRESSION OF RESPONDING BY
VISUAL AND AUDITORY STIMULI. Many neu-
rotoxic agents produce deficits in visual and audi-
tory processing. For instance, the ototoxicity of
methylmercury and kanamycin are well known.
Conditioned suppression techniques have been
used by various investigators to determine the ef-
fects of chemicals on sensory processing (36).
Food-deprived rats will be trained to press alever
on a variable-interval 20 sec schedule. Conditioned
suppression of schedule-controlled responding will
be established using visual or auditory stimuli
paired with electric footshock. After obtaining a
stable baseline and appropriate suppression of re-
sponding, the rats will be assigned to treatment
groups and dosed accordingly. Sessions will be
conducted 4 days a week for the duration of the
study. Average rates ofresponding and suppression
ratios to visual and auditory stimuli will be mea-
sured.
TEMPORAL DISCRIMINATION. The ability ofrats
to maintain a discrimination between two signals
differing only in duration is known to be affected by
chemical administration (37). Further, toxicosis is
frequently reported to affect short-term memory. In
this study, rats will be trained to discriminate be-
tween two temporal durations (nominally 2 vs. 8
sec) prior to the initiation ofthe dosing regime. The
discrimination procedure will be continued through
90 days of dosing and 30 days post-dosing on a
Monday-Wednesday-Friday schedule. During dos-
ing, a variable interval (0-15 sec) delay will be inter-
posed between the end of the signal and the ani-
mals' opportunity to respond to it; differences in
accuracy of discrimination should be inversely re-
lated to the length ofthe delay interval. Accuracy of
the discrimination as a function ofdose level, delay
length, and dosing period will be monitored. La-
tency of correct and incorrect responses and pro-
portion of left and right responses (response bias)
will also be recorded.
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The neurotoxins that will be studied were
selected according to the criteria outlined above. In
the following section, information is provided about
candidate substances to be tested, as well as the
symptomatology reported in humans.
Agents Producing Demyelination of Nerve
Tissue. Triethyltin (TET) and other organotin
compounds are environmentally prevalent chemi-
cals used for a variety ofpurposes, such as mollus-
cicides, algicides, fungicides, and insecticides (38,
39). The neurotoxicity of TET is well documented
in humans, in which it produces numerous signs of
central toxicity, including psychological and visual
disturbances and photophobia. Other signs of
poisoning include urine retention, vertigo, abdomi-
nal pain, weight loss, and hypothermia. Transient
pareses and occasionally paralysis have also been
observed (40-42).
Agents Producing a "Dying-Back" Axonal
Neuropathy. Acrylamide (ACR) has many in-
dustrial uses, waterproofing, strengthening ofpaper
and chipboard, and some types offlocculating pro-
cesses among them (43). This substance produces a
"dying-back" neuropathy similar to that resulting
from neurotoxic organophosphates such as tri-o-
cresyl phosphate. The effects of acrylamide in ani-
mals closely resemble those observed in humans,
hence its use in recent years as a model compound
in the study of "'dying-back" polyneuropathies (44,
45). The symptomatology and morphological effects
ofacrylamide in humans and animals have been re-
cently reviewed (43-45). Initial signs of poisoning
include weight loss, fatigue and paresthesias, with
numbness in the hands and feet. Weakness in the
hands and legs also have an early onset, and fine
movements of the hands are impaired. Ataxia and
depression of tendon reflexes in the arms and legs
are observed, while responses to nociceptive
stimulation seem intact. With continued intoxica-
tion, more proximal regions ofthe body are affected
and paralysis and death may result. Tremor and
bladder incontinence have been reported less fre-
quently. Termination of exposure to acrylamide
usually results in an improvement in function, the
extent ofwhich depends upon the dose and duration
of exposure.
Agents Producing Mixed Central and
PeripheralNeuropathies. Mercury is apersistent
environmental pollutant that has followed the use of
mercurials as antifungal agents, slimicides, mildew
preventives, and chemical catalysts. Compounds
containing mercury have also been used as phar-
maceutical agents and in the manufacture of elec-
tronic components (46). Organic mercury com-
pounds such as methylmercury are highly toxic and
produce mixed peripheral and central neuropathies
(46). Clinically, methylmercury results in a gradual
onset of a cluster of symptoms characterized by
neurasthenia, weakness, fatigue, headache, mem-
ory deficits, emotional irritability, and mood alter-
ations. With continued exposure, methylmercury
produces paresthesias and generalized ataxia fol-
lowed by spasticity and tremor, hearing and visual
deficits and eventually coma and death.
Agents Attacking Specific CNS Nuclear
Groups. An example of this category is man-
ganese or its salts, which occur frequently in many
industrial and mining environments. Overexposure
to these agents can produce symptoms which in
many respects resemble those of Parkinson's dis-
ease (47, 48). Since the extrapyramidal symp-
tomatology of this syndrome is associated with the
deterioration of dopamine-containing pathways in
the CNS (49), it has been suggested that manganese
may also act on these pathways (48). These obser-
vations indicate that the study ofmanganese is rele-
vant to the interests of our program. However, it
was decided not to include manganese at this time
since it has been asserted that albino rats do not
display the typical behavioral and neurological signs
associated with manganese toxicity in humans (50).
Manganese has been reported to produce ex-
trapyramidal dysfunction in monkeys and apes (51),
and this substance will be considered whenever
these species are available for study at the Institute.
Other examples of selective neurotoxins, e.g.,
gold thioglucose, 6-hydroxydopamine, and 5,6-
dihydroxytryptamine, were also considered. These
agents are not included in the present test battery
due to a lack of species generality, inadequate data
base, or absence of environmental relevance.
Agents That Produce Anoxia. Norton (14) dis-
cusses several types of compounds that affect me-
tabolism in neuronal tissue by altering the availabil-
ity of oxygen. Some toxic substances produce
anoxia by acting directly on the cardiovascular
system and are not relevant to the immediate goals
of the program. On the other hand, carbon
monoxide, which decreases the amount of oxygen
reaching tissue by binding preferentially to hemo-
globin, is an environmental toxin with well
documented effects on the CNS. Nevertheless,
study ofthis compound is not presently feasible be-
cause inhalation facilities meeting the highly varied
needs of the program have yet to be developed.
Another substance considered was cyanide, which
inhibits cellular respiration and produces a
cytotoxic anoxia. Since cyanide produces demyeli-
nation of white matter in the corpous callosum and
associated brain regions in a manner similar to
October 1978 295triethyltin (52) and since it was desirable to compare
the behavioral effects of neurotoxins having differ-
ent mechanisms ofactions, the study ofcyanide will
be deferred to a later time.
Reference Psychopharmacological Agents
In addition to representative neurotoxins from
the schema of Norton (14), two drugs that have
known acute and subacute effects will be assessed
in some of the more critical tests of the proposed
battery. The information derived from these
psychopharmacological standards will help in the
interpretation of data obtained from studies with
triethyltin, acrylamide, and methylmercury.
Amphetamine. Amphetamine (AMP) is a CNS
stimulant that has been used at various times in the
treatment of obesity, depression, narcolepsy, and
more recently, the so-called hyperkinetic syndrome
in children. Amphetamine has marked CNS stimu-
lant and analeptic effects. When given in high
enoug} doses or repeatedly, amphetamine may re-
sult in tremor, sterotypic motor movements and
agitation. In addition, a well-defined psychological
syndrome that resembles paranoid schizophrenia
has been described in humans (53). The administra-
tion of very high doses of amphetamine and
methamphetamine has been reported to produce
morphological changes in the brain that appearto be
related to the resultant cardiovascular effects (54).
The effects ofrepeated amphetamine administration
on animal behavior have been extensively studied
(55, 56) and have been found to be highly dependent
upon pharmacological variables, such as dose and
dosing schedule, and behavioral variables, such as
the response measured and the schedule of rein-
forcement (57-59).
Sodium Salicylate. Aspirin is a ubiquitous in-
gredient in many medications. The chronic inges-
tion of relatively high doses of sodium salicylate
(SAL) produces a cluster of symptoms including
tinnitus, dizziness, confusion, apathy, and loss of
hearing (60). These effects are generally reversible.
The effects of salicylates on a variety of responses
controlled by auditory cues has been described re-
cently by Hanson (61). It is because ofthe relatively
selective effect ofsalicylate on hearing function and
the potential for possible interaction with numerous
environmental chemicals that we chose it as a refer-
ence psychopharmacological agentforour studies.
Predicted Effects of
Representative Compounds in
Behavioral Tests
Ifthe conditions under which the behavioral and
neurological assessments described above are to be
made relevant to the signs and symptoms ofhuman
toxicosis, it follows then that predictions should be
made as to the outcome of tests with the animal
model. Indeed, such predictions are necessary in
order to demonstrate the adequacy ofany given test
system, in two senses.
First, prediction ofoutcomes validates the animal
models, in a somewhat limited way, for the class of
symptom and the class of neurotoxin in question.
As our ability to make such predictions grows (as it
must), the efficiency and concomitant economy of
behavioral and neurological toxicology is enhanced.
Secondly, predictions which are not upheld are
still useful, perhaps even more so than correct pro-
jections. When a prediction for a particular
procedure-agent combination is not upheld, we ex-
pose for further intensive examination a gap in our
knowledge, either about the animal model, the pa-
rameters of test, the procedure itself or some com-
bination of these. This information can then aid in
the evolution of new more refined procedures
and/or in the evaluation of the classification
scheme, and particularly of the mechanism of the
compound in question. Somewhat similarly, the
pattern of correct and incorrect predictions may
point out inadequacies of the entire test system,
leading again to reconsideration of the factors in-
volved in choice of an animal model, choice oftest
procedures, and decisions about the efficiency of
the total set of assessment conditions. In short,
then, a comparison of the observed results with
predicted outcomes is a critical aspect of this re-
search.
In order to make the desired comparisons, it was
necessary to review the human toxicology of the
five compounds chosen for study and to establish a
symptomatologic profile characteristic of each
agent. We then listed the neurobehavioral tests
selected for validation in the animal model and gen-
erated a pattern of expected effects. Table 4 sum-
marizes these predictions in terms of the presence
or absence of an effect, the direction of any effect,
the time when an effect may be expected (i.e., first
or last half of the dosing phase), and the reversibil-
ity or delayed appearance of an effect once dosing
has ceased. After all of the compounds have been
studied and a profile of observed effects is avail-
able for comparison with the expected effects, it
will be possible to make some tentative conclusions
concerning the validity of each test. Those tests
correctly predicting the occurrence, onset, dura-
tion, and reversibility ofan effect meet the criterion
for predictive validity discussed above. Tests sup-
posed to measure the same function or process will
also be compared for sensitivity, orthe dosage level
at which an effect is noted, and for selectivity, or
the capability to indicate an effect where one is ex-
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0-45 days 45-90 days Post-dosing (120 days)
Behavioral test ACR TET MM AMP SAL ACR TET MM AMP SAL ACR TET MM AMP SAL
Domiciliary
Motoractivity 40 0 4 4 0 0 0 4 4 0
Food intake 0 0 0 4 0 4 4 4 0 0 0 0 4 0
Waterintake 0 0 0 T 0 4 T 0 0 0 4 1 0
Geophagia 1 T T 0 0 T T T 0 T 0 0 0 0 0
Primary screen
Neurological screen
and general health
Autonomics 0 0 0 t 0 0 0 0 0 0 0 0 0 0 0
Reflexes 4 4 0 0 0 1 1 1 1 0 0 0 4 0 0
Rectal temperature 0 1 0 1 0 0 4 0 0 0 0 0 0 0 0
Body weight 0 0 0 1 0 4 4 4 1 1 1 0 4 0 0
Motoractivity 4 4 0 T 0 4 4 4 1 0 0 0 4 1 0
Forelimb grip 0 0 0 1 0 4 4 0 0 0 4 0 0
Hindlimb extension 4 0 0 1 0 4 4 4 t 0 0 0 4 0 0
Inclined screen 4 0 0 0 0 4 4 4 0 1 0 0 4 0 0
Startle 0 0 0 t 0 0 1 T 1 0 0 0 T 0 0
One-way avoidance 0 0 0 0 0 1 1 1 0 0 0 0 4 0 0
Tremor 0 0 0 1 0 0 0 t T 0 0 0 T 0 0
Special
Pain threshold 4 0 4 t 0 4 0 4 0 0 0 0 4 0 0
Temporal discrimination
Accuracy
Zero delay 0 0 0 4 0 0 0 4 0 0 0 0 4 0 0
Max delay 0 0 4 4 0 0 0 4 0 0 0 0 4 0 0
Latency
Zero delay T T 0 0 0 T 1 T 0 0 0 0 T 0 0
Max delay t T 0 0 0 T 1 1 0 0 0 0 T 0 0
Unsignalled continuous
avoidance
Avoidances 4 4 0 T 0 4 4 4 1 0 0 0 4 0 0
Escapes T T 0 0 0 1 T 1 0 0 0 0 1 0 0
Escape losses 0 0 0 0 0 1 1 T 0 0 0 0 T 0 0
Conditioned suppression
Visual, accuracy 0 0 0 4 0 0 0 0 0 0 4 0 0
Visual, latency t 1 0 0 0 T t T 0 0 0 0 1 0 0
Auditory, accuracy 0 0 0 1 0 0 0 4 0 1 0 0 4 0 0
Auditory, latency T T 0 T 0 4 0 0 0 1 0 0
Shuttle box
Avoidances 40 0 4 4 0 0 0 4 0 0
Escapes T 1 0 0 0 T t T 0 0 0 0 t 0 0
Escapes losses 0 0 0 0 0 1 t T 0 0 0 0 1 0 0
a Response: T = measure is predicted to be elevated or rate increased; 4 = predicted to be decreased in magnitude or rate decreased;
0 = no significant alteration in the measure is expected.
pected and no effect where none is expected.
We believe that the test validation scheme dis-
cussed in this paper represents a critical step for the
growth ofbehavioral and neurological toxicology as
a scientific discipline.. Science rests squarely upon
the foundation of appropriate methodology. There
must be credibility and confidence in the
methodological tools of the trade before steps can
be made to assess our environmental problems in a
meaningful way.
We gratefully acknowledge the direction and insightful
suggestions of Dr. Clifford L. Mitchell, Chief, Laboratory of
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